669 related articles for article (PubMed ID: 29294040)
1. How to master the host immune system? Leishmania parasites have the solutions!
Rossi M; Fasel N
Int Immunol; 2018 Mar; 30(3):103-111. PubMed ID: 29294040
[TBL] [Abstract][Full Text] [Related]
2. Role of pro-inflammatory cytokine IL-17 in Leishmania pathogenesis and in protective immunity by Leishmania vaccines.
Banerjee A; Bhattacharya P; Joshi AB; Ismail N; Dey R; Nakhasi HL
Cell Immunol; 2016 Nov; 309():37-41. PubMed ID: 27444130
[TBL] [Abstract][Full Text] [Related]
3. Identifying vaccine targets for anti-leishmanial vaccine development.
Sundar S; Singh B
Expert Rev Vaccines; 2014 Apr; 13(4):489-505. PubMed ID: 24606556
[TBL] [Abstract][Full Text] [Related]
4. Leishmania model for microbial virulence: the relevance of parasite multiplication and pathoantigenicity.
Chang KP; Reed SG; McGwire BS; Soong L
Acta Trop; 2003 Mar; 85(3):375-90. PubMed ID: 12659975
[TBL] [Abstract][Full Text] [Related]
5. Leishmaniasis: complexity at the host-pathogen interface.
Kaye P; Scott P
Nat Rev Microbiol; 2011 Jul; 9(8):604-15. PubMed ID: 21747391
[TBL] [Abstract][Full Text] [Related]
6. Toll-like receptor signaling: a perspective to develop vaccine against leishmaniasis.
Singh RK; Srivastava A; Singh N
Microbiol Res; 2012 Sep; 167(8):445-51. PubMed ID: 22326459
[TBL] [Abstract][Full Text] [Related]
7. Subversion of host cell signalling by the protozoan parasite Leishmania.
Gregory DJ; Olivier M
Parasitology; 2005; 130 Suppl():S27-35. PubMed ID: 16281989
[TBL] [Abstract][Full Text] [Related]
8. Leishmaniasis in humans: drug or vaccine therapy?
Ghorbani M; Farhoudi R
Drug Des Devel Ther; 2018; 12():25-40. PubMed ID: 29317800
[TBL] [Abstract][Full Text] [Related]
9. NKT cells in leishmaniasis.
Zamora-Chimal J; Hernández-Ruiz J; Becker I
Immunobiology; 2017 Apr; 222(4):641-646. PubMed ID: 28012583
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of anti-leishmanial effects of killed Leishmania vaccine with BCG adjuvant in BALB/c mice infected with Leishmania major MRHO/IR/75/ER.
Nahrevanian H; Jafary SP; Nemati S; Farahmand M; Omidinia E
Folia Parasitol (Praha); 2013 Feb; 60(1):1-6. PubMed ID: 23539946
[TBL] [Abstract][Full Text] [Related]
11. Understanding the immune responses involved in mediating protection or immunopathology during leishmaniasis.
Pacheco-Fernandez T; Volpedo G; Verma C; Satoskar AR
Biochem Soc Trans; 2021 Feb; 49(1):297-311. PubMed ID: 33449103
[TBL] [Abstract][Full Text] [Related]
12. Determinants of Innate Immunity in Visceral Leishmaniasis and Their Implication in Vaccine Development.
Volpedo G; Pacheco-Fernandez T; Bhattacharya P; Oljuskin T; Dey R; Gannavaram S; Satoskar AR; Nakhasi HL
Front Immunol; 2021; 12():748325. PubMed ID: 34712235
[TBL] [Abstract][Full Text] [Related]
13. The Dialogue of the Host-Parasite Relationship: Leishmania spp. and Trypanosoma cruzi Infection.
de Morais CG; Castro Lima AK; Terra R; dos Santos RF; Da-Silva SA; Dutra PM
Biomed Res Int; 2015; 2015():324915. PubMed ID: 26090399
[TBL] [Abstract][Full Text] [Related]
14. Host immune response against leishmaniasis and parasite persistence strategies: A review and assessment of recent research.
Elmahallawy EK; Alkhaldi AAM; Saleh AA
Biomed Pharmacother; 2021 Jul; 139():111671. PubMed ID: 33957562
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of vaccinal effectiveness of preparations containing membrane antigens of Leishmania (L.) amazonensis in experimental cutaneous leishmaniasis model.
Ribeiro JG; Ferreira AS; Macedo SRA; Rossi NRDLP; da Silva MCP; Guerra RNM; de Barros NB; Nicolete R
Int Immunopharmacol; 2017 Jun; 47():227-230. PubMed ID: 28433944
[TBL] [Abstract][Full Text] [Related]
16. [Immunopathogenesis of Leishmania infections].
Yurdakul P
Mikrobiyol Bul; 2005 Jul; 39(3):363-81. PubMed ID: 16358498
[TBL] [Abstract][Full Text] [Related]
17. Interaction of Leishmania with the host macrophage.
Handman E; Bullen DV
Trends Parasitol; 2002 Aug; 18(8):332-4. PubMed ID: 12377273
[TBL] [Abstract][Full Text] [Related]
18. Leishmanial apolipoprotein A-I expression: a possible strategy used by the parasite to evade the host's immune response.
Kalantar K; Manzano-Román R; Ghani E; Mansouri R; Hatam G; Nguewa P; Rashidi S
Future Microbiol; 2021 May; 16():607-613. PubMed ID: 33998267
[TBL] [Abstract][Full Text] [Related]
19. Pleiotropic Effect of Hormone Insulin-Like Growth Factor-I in Immune Response and Pathogenesis in Leishmaniases.
Reis LC; Ramos-Sanchez EM; Araujo FN; Leal AF; Ozaki CY; Sevillano OR; Uscata BA; Goto H
J Immunol Res; 2021; 2021():6614475. PubMed ID: 34036108
[TBL] [Abstract][Full Text] [Related]
20. Cross-protective efficacy from a immunogen firstly identified in Leishmania infantum against tegumentary leishmaniasis.
Martins VT; Lage DP; Duarte MC; Costa LE; Chávez-Fumagalli MA; Roatt BM; Menezes-Souza D; Tavares CA; Coelho EA
Parasite Immunol; 2016 Feb; 38(2):108-17. PubMed ID: 26756314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
